- Home
- SHMD vs CCCC Comparison
SHMD vs CCCC Comparison
Compare SHMD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- CCCC
- Stock Information
- Founded
- SHMD 1864
- CCCC 2015
- Country
- SHMD Germany
- CCCC United States
- Employees
- SHMD N/A
- CCCC N/A
- Industry
- SHMD
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- CCCC Health Care
- Exchange
- SHMD Nasdaq
- CCCC Nasdaq
- Market Cap
- SHMD 128.3M
- CCCC 104.4M
- IPO Year
- SHMD N/A
- CCCC 2020
- Fundamental
- Price
- SHMD $3.04
- CCCC $2.32
- Analyst Decision
- SHMD
- CCCC Buy
- Analyst Count
- SHMD 0
- CCCC 3
- Target Price
- SHMD N/A
- CCCC $12.00
- AVG Volume (30 Days)
- SHMD 30.7K
- CCCC 1.9M
- Earning Date
- SHMD 02-25-2025
- CCCC 07-31-2025
- Dividend Yield
- SHMD N/A
- CCCC N/A
- EPS Growth
- SHMD N/A
- CCCC N/A
- EPS
- SHMD N/A
- CCCC N/A
- Revenue
- SHMD $85,165,542.00
- CCCC $39,783,000.00
- Revenue This Year
- SHMD N/A
- CCCC N/A
- Revenue Next Year
- SHMD N/A
- CCCC N/A
- P/E Ratio
- SHMD N/A
- CCCC N/A
- Revenue Growth
- SHMD N/A
- CCCC 98.56
- 52 Week Low
- SHMD $1.86
- CCCC $1.09
- 52 Week High
- SHMD $4.98
- CCCC $7.36
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- CCCC 67.05
- Support Level
- SHMD N/A
- CCCC $1.92
- Resistance Level
- SHMD N/A
- CCCC $2.41
- Average True Range (ATR)
- SHMD 0.00
- CCCC 0.25
- MACD
- SHMD 0.00
- CCCC 0.06
- Stochastic Oscillator
- SHMD 0.00
- CCCC 70.61
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.